


Status: Currently Official on 17-Feb-2025  
 Official Date: Official as of 01-Nov-2023  
 Document Type: USP Monographs  
 DocId: GUID-E9E474E4-A5CA-4856-A62B-9C4527DB9668\_5\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M87400\\_05\\_01](https://doi.org/10.31003/USPNF_M87400_05_01)  
 DOI Ref: xuu8v

© 2025 USPC  
 Do not distribute

## Urea



$\text{CH}_4\text{N}_2\text{O}$  60.06

Urea;

Carbamide CAS RN®: 57-13-6; UNII: 8W8T17847W.

### DEFINITION

Urea contains NLT 98.0% and NMT 102.0% of urea ( $\text{CH}_4\text{N}_2\text{O}$ ).

### IDENTIFICATION

- A. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197K](#)
- B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### • PROCEDURE

**Solution A:** Transfer 1 mL of formic acid to a 1-L volumetric flask and dilute with water to volume.

**Solution B:** 100% Acetonitrile, passed through a membrane filter of 0.2-μm pore size

**Mobile phase:** See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0.0	2.5	97.5
7.0	10.0	90.0
7.01	2.5	97.5
15.0	2.5	97.5

**Diluent:** Acetonitrile and water (90:10)

**System suitability solution:** 0.01 mg/mL of [USP Urea Related Compound A RS](#) and 10 mg/mL of [USP Urea RS](#) in *Diluent*

**Standard solution:** 5 mg/mL of [USP Urea RS](#) in *Diluent*

**Sample solution:** 5 mg/mL of Urea in *Diluent*

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 195 nm

**Column:** 15-cm × 4.6-mm; 2.7-μm packing L86

**Column temperature:** 30°

**Flow rate:** 1 mL/min

**Injection volume:** 2 μL

#### System suitability

**Sample:** *System suitability solution*

[NOTE—The relative retention times for urea related compound A and urea are 0.9 and 1.0, respectively.]

#### Suitability requirements

**Resolution:** NLT 1.5 between urea related compound A and urea

**Relative standard deviation:** NMT 1.0% for urea

#### Analysis

**Samples:** Standard solution and Sample solution

Calculate the percentage of urea ( $\text{CH}_4\text{N}_2\text{O}$ ) in the portion of Urea taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response from the Sample solution

$r_S$  = peak response from the Standard solution

$C_S$  = concentration of [USP Urea RS](#) in the Standard solution (mg/mL)

$C_U$  = concentration of Urea in the Sample solution (mg/mL)

**Acceptance criteria:** 98.0%–102.0%

#### IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

• **ORGANIC IMPURITIES**

**Solution A, Solution B, Mobile phase, Diluent, and Chromatographic system:** Proceed as directed in the Assay.

**System suitability solution:** 0.01 mg/mL of [USP Urea Related Compound A RS](#) and 10 mg/mL of [USP Urea RS](#) in Diluent

**Standard solution:** 0.01 mg/mL of [USP Urea RS](#) and 0.01 mg/mL of [USP Urea Related Compound A RS](#) in Diluent

**Sample solution:** 10 mg/mL of Urea in Diluent

#### System suitability

**Sample:** System suitability solution

[NOTE—For the relative retention times, see [Table 2](#).]

#### Suitability requirements

**Resolution:** NLT 1.5 between urea and urea related compound A

**Relative standard deviation:** NMT 1.0% for urea

#### Analysis

**Samples:** Standard solution and Sample solution

Calculate the percentage of urea related compound A in the portion of Urea taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of urea related compound A from the Sample solution

$r_S$  = peak response of urea related compound A from the Standard solution

$C_S$  = concentration of [USP Urea Related Compound A RS](#) in the Standard solution (mg/mL)

$C_U$  = concentration of Urea in the Sample solution (mg/mL)

Calculate the percentage of any individual unspecified impurity in the portion of Urea taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of any impurity from the Sample solution

$r_S$  = peak response of urea from the Standard solution

$C_S$  = concentration of [USP Urea RS](#) in the Standard solution

$C_U$  = concentration of Urea in the Sample solution

**Acceptance criteria:** See [Table 2](#). Disregard any impurity peaks less than 0.05%.

**Table 2**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Urea related compound A	0.9	0.1
Urea	1.0	—
Any individual unspecified impurity	—	0.1
Total impurities	—	2.0

## SPECIFIC TESTS

*Change to read:*

• **ALCOHOL-INSOLUBLE MATTER**

**Sample solution:** ▲ Dissolve 5.0 g of Urea in 50 mL of warm alcohol.▲ (ERR 1-Nov-2023)

**Analysis:** If any insoluble residue remains, pass the *Sample solution* through a tared filter, wash the residue and the filter with 20 mL of warm alcohol▲ (ERR 1-Nov-2023), and dry at 105° for 1 h.

**Acceptance criteria:** NMT 2 mg (0.04%)

• **STERILITY TESTS (71):** Where the label states that Urea is sterile, it meets the requirements.

• **BACTERIAL ENDOTOXINS TEST (85):** Where the label states that Urea must be subjected to further processing during the preparation of injectable dosage forms, it contains NMT 0.003 USP Endotoxin Units/mg of urea.

## ADDITIONAL REQUIREMENTS

• **PACKAGING AND STORAGE:** Preserve in well-closed containers. Store at 25°, excursions permitted between 15° and 30°.

• **LABELING:** Where it is intended for use in preparing injectable dosage forms, the label states that it is sterile or must be subjected to further processing during the preparation of injectable dosage forms.

• **USP REFERENCE STANDARDS (11):**

[USP Urea RS](#)

[USP Urea Related Compound A RS](#)

Dicarbonimidic diamide.

C2H5N3O2 103.08

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
UREA	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM22020 Small Molecules 2

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 40(4)

**Current DocID: GUID-E9E474E4-A5CA-4856-A62B-9C4527DB9668\_5\_en-US**

**DOI:** [https://doi.org/10.31003/USPNF\\_M87400\\_05\\_01](https://doi.org/10.31003/USPNF_M87400_05_01)

**DOI ref:** [xuu8v](#)